Ibrutinib, a Bruton's tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test …

JA Regan, Y Cao, MC Dispenza, S Ma… - Journal of Allergy and …, 2017 - jacionline.org
Neutropenia has also been noted as a side effect in clinical trials with a frequency ranging
from 15% to 22% of patients. 3-5 Regarding effects on allergic cell reactivity, Advanti et al 6
reported inhibition of IgE-dependent basophil activation in subjects receiving ibrutinib as
determined ex vivo using the basophil activation test (BAT). In vitro studies done by
MacGlashan et al 7 showed that ibrutinib, tested at clinically relevant concentrations,
completely blocked FcεRI-dependent basophil release of histamine and leukotrienes …